Search / Trial NCT00002103

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia

Launched by U.S. BIOSCIENCE · Aug 30, 2001

Trial Information

Current as of November 03, 2024

Completed

Keywords

Trimetrexate Pneumonia, Pneumocystis Carinii Leucovorin Drug Therapy, Combination Acquired Immunodeficiency Syndrome

Description

Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. Patients are followed for 1 month.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • * Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.
  • * Serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, OR a documented history of such intolerance during a prior episode.
  • * Consent of parent or guardian if less than 18 years of age.
  • Exclusion Criteria
  • Patients with the following prior conditions are excluded:
  • History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.

About U.S. Bioscience

U.S. Bioscience is a leading clinical trial sponsor dedicated to advancing innovative therapies and treatments in the biomedical field. With a strong focus on developing solutions for unmet medical needs, the organization leverages cutting-edge research and technology to drive clinical development and ensure patient safety. U.S. Bioscience collaborates with a network of experienced researchers, healthcare professionals, and regulatory bodies to facilitate robust clinical trials that adhere to the highest standards of quality and ethics. Committed to improving health outcomes, U.S. Bioscience strives to bring transformative therapies from the laboratory to the marketplace, enhancing the quality of life for patients worldwide.

Locations

West Conshohocken, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials